Alpha Tau Medical (DRTS) CFO Raphi Levy Sells $167K of Stock

Raphi Levy, the Chief Financial Officer of Alpha Tau Medical Ltd. (NasdaqCM: DRTS), sold 17,500 shares of the company on June 23, 2026. The shares were sold at an average price of $9.55, amounting to a total transaction value of $167,049. This sale was part of a pre-planned trading strategy under Rule 10b5-1.

Insider Buying and Selling at Alpha Tau Medical Ltd.

Raphi Levy has been actively trading shares of Alpha Tau Medical. On June 23, 2026, he sold 17,500 shares at $9.55 each in a planned transaction. Earlier in the month, on June 3, Levy sold 32,500 shares at an average price of $10.84. Other significant sales this year included 10,000 shares at $7.40 on February 25 and 15,000 shares at $7.09 on January 13, both under planned sales.

Other Institutional Activity in Alpha Tau Medical

Institutional investors have been making moves in Alpha Tau Medical as well. HIGHTOWER ADVISORS, LLC increased its holdings by 188,440 shares, bringing its total to 874,994 shares valued at about $6.19 million, a 27.4% increase. AQUAMARINE FINANCIAL (CAYMAN) LTD opened a new position with 721,501 shares worth approximately $5.10 million. UBS GROUP AG significantly boosted its stake by 265,988 shares, now holding 286,688 shares valued at around $2.03 million, reflecting a 1,285% increase.

Alpha Tau Medical Ltd. Stock Down 28.3%

Shares of Alpha Tau Medical Ltd. traded near $10.93 on Friday. The company, which focuses on oncology therapeutics, boasts a market capitalization of roughly $1.01 billion. It has a forward P/E ratio of -21.7, indicating it is not currently profitable. The stock's 52-week range is between $2.87 and $11.62, with a 50-day moving average of $9.26 and a 200-day moving average of $6.46.

Analysts Set New Price Targets

Analysts have been actively covering Alpha Tau Medical. On June 4, 2026, Barclays maintained its 'buy' rating with a price target of $17. Ladenburg Thalmann and HC Wainwright & Co. also maintain 'buy' ratings, with targets of $14 and $15, respectively. Piper Sandler has a 'hold' rating with a target of $8, reflecting mixed sentiments among analysts. The consensus recommendation is a 'buy' with a mean target price of $14.20 based on five analyst opinions.

About Alpha Tau Medical

Alpha Tau Medical Ltd., headquartered in Jerusalem, Israel, is a clinical-stage biotechnology company. It specializes in the development of Alpha DaRT, a therapy using alpha-emitters radiation for treating solid tumors. The company is actively conducting clinical trials for a range of cancers including skin, oral, and pancreatic. Led by CEO Uzi Sofer, Alpha Tau Medical employs 121 people and continues to focus on innovative cancer treatments.

Bottom Line

Raphi Levy's recent stock sales are part of a planned strategy, common for executives managing their holdings. Investors track these insider activities for insights into management's confidence. Alpha Tau Medical's stock shows active interest from institutional investors and analysts, reflecting its potential in the biotechnology sector.